Screening for Breast Cancer: An Overview

Skrabanek P. The debate over mass mammography in Britain. Br Med J 1988; 297: 970–971.

Roberts M. Breast screening: Time for a rethink? BMJ 1989; 299: 1153–1155.

Baum M. Statement - Sunday Times September 3rd 1995.

Wright CJ , Mueller CB. Screening mammography and public health policy: The need for perspective. Lancet 1995; 346: 29–32.

Cancer Research UK. UK Breast Cancer Incidence and Mortality Statistics. July 2007.

Editorial. Reduction in mortality from breast cancer. Br Med J 2005; 330: 205–206.

West Midlands Cancer Intelligence Unit. ABS at BASO Breast Screening Audit 2006-2007 presented at BASO meeting, June 2008. NHS Cancer Screening Programmes.

Joensuu H , Tolkkanew S. Comparison of breast carcinomas diagnosed in the 1980s with those diagnosed in the 1940s to 1960s. Br Med J 1991; 303: 155–158.

Gillis CR , Hole D. Survival outcome of cancer by specialist surgeons in breast cancer - a study of 3786 patients in the west of Scotland. Br Med J 1996; 312: 145–148.

Miller WR , Ellis IO , Sainsbury JRC. ABC of breast diseases - prognostic factors. Br Med J 1994; 309: 1573–1576.

Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post menopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288: 321–333.

Coombs N , Taylor R , Wilcken N. Hormone replacement therapy and breast cancer: Impact on population risk and incidence. Eur J Cancer 2003; 41: 1775–1781.

Ahn J , Schatzkin A , Lacey JV. Adiposity, adult weight change and post menopausal breast cancer risk. Arch Intern Med 2007; 167: 2091–2102.

Hancock SL , Tucker MA , Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Can Inst 1993; 85: 25–31.

The challenge of evaluating annual mammography screening for young women with a family history of breast cancer. The FHO1 Management Committee, Steering Committee, Collaborators. J Med Screen 2006; 13: 177–182.

Miki Y , Swensen J , Shattuck-Eidens E. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71.

Wooster R , Bignall G , Lancaster J. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789–792.

Li CI , Malone KE , Porter PL. Relationship between long duration and different regimens of hormone therapy and risk of breast cancer. JAMA 2003; 289: 3254–3263.

Reeves G , Beral V , Green J. On behalf of the million women study collaboratives. Hormone therapy for menopause and breast cancer risk by histological type: A cohort study and meta-analysis. Lancet Oncology 2006; 9: 910–918.

Stallard S , Litherland JC , Cordiner C. Hormone replacement therapy does not influence pathological stage of breast cancer: A population based cross sectional study. Eur J Surg Onc 1996; 23: 586–589.

Carter GL , Allen C , Henson DE. Relation of tumour size, lymph node status and survival in 24,741 breast cancer cases. Cancer 1989; 63: 181–187.

Miller AB , Bulbrook RD. UICC multidisciplinary project on breast cancer: The epidemiology, etiology and prevention of breast cancer. Int J Cancer 1986; 37: 173–177.

Richards MA , Smith IE , Dixon JM. ABC of breast diseases - role of systemic treatment for primary operable breast cancer. Br Med J 1994; 309: 1363–1366.

Bundred NJ , Morgan DAL , Dixon JM. ABC of breast diseases - management of regional nodes in breast cancer. Br Med J 1994; 309: 1222–1225.

Shapiro S , Venet W , Strax P. Ten to fourteen year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982; 69: 349–355.

Tabár L , Fagerberg CJG , Gad A. Reduction in mortality from breast cancer after mass screening with mammography; randomised trial from the breast cancer screening working group of the Swedish National Board of Health and Welfare. Lancet 1985; 1: 829–832.

Forrest P. Breast Cancer Screening. A report to the Health Ministers of England, Scotland and Northern Ireland, London: HMSO, 1986.

Subcommittee of the Radiological Advisory Committee of the Chief Medical Officer. Report of the Subcommittee of the Radiological Advisory Committee of the Chief Medical Officer: Quality Assurance Guidelines for Mammography (Pritchard Report). London: NHSBSP Publications, 1989.

Parker SH , Lovin JD , Jobe WE. Stereotactic breast biopsy with a biopsy gun. Radiology 1990; 76: 741–747.

Parker SH , Lovin JD , Jobe WE. Non palpable breast lesions: Stereotactic automated large core biopsies. Radiology 1991; 180: 403–407.

Parker SH , Burbank F , Jackman RJ. Percutaneous large core breast biopsy: A multidisciplinary study. Radiology 1994; 193: 350–364.

Parker SH. Percutaneous large core breast biopsy. Cancer 1994; 74: (1 suppl) 256–262.

Houssami N , Ciatto S , Ambrogetti D. Florence - Sydney Breast Biopsy Study: Sensitivity of ultrasound guided versus freehand fine needle biopsy of palpable breast cancer. Breast Cancer Res Treat 2005; 89: 55–59.

Wald NJ , Murphy P , Major P. UKCCCR multicentre randomised controlled trials of one and two view mammography in breast cancer screening. BMJ 1995; 311: 1189–1193.

Blanks RG , Given-Wilson RM , Moss SM. Efficiency of cancer detection during routine repeat (incident) mammographic screening: Two versus one view mammography. J Med Screen 1998; 5: 141–145.

Chen HH , Tabár L , Fagerberg G. Effect of breast cancer screening after the age 65. J Med Screen 1995; 2: 10–14.

Editorial. Will you still need me, will you still screen me, when I'm past 64? Br Med J 1997; 315: 1032–1033.

Henry P J , Entwistle C. Effect of issuing an invitation for breast cancer screening to women aged 65 to 69. J Med Screen 1996; 3: 88–89.

Van Der Pot M , Cairns J. Predicting attendance for breast screening using routinely collected data. Health Care Management Science 2004; 6: 229–236.

Scottish Breast Screening Programme Development Task Group. Report on Extending Age Range for Invitation to Breast Screening. SBSP Publications, 2001.

The Breast Screening Frequency Trial Group. The frequency of breast cancer screening: Results from the UKCCCR randomised trial. Eur J Cancer 2002; 38: 1458–1464.

Thurfell EL , Lindgren JAA. Breast cancer survival rates with mammographic screening: Similar favourable survival rates for women younger and those older than 50 years. Radiology 1996; 201: 421–426.

Smart CR , Hendrick RE , Rutledge JH. Benefit of mammography screening in women ages 40-50 years. Cancer 1995; 75: 1619–1626.

The Organising Committee and Collaborators (Falun Consensus Conference). Breast cancer screening with mammography in women aged 40-49 years. Int J Cancer 1996; 58: 693–699.

Moss SM , Cuckle H , Evans A (on behalf of the Trial Management Group). Effect of mammographic screening from age 49 years on breast cancer mortality at 10 years follow-up. A randomised controlled trial. Lancet 2006; 368: 2053–2060.

Department of Health: Cancer Reform Strategy. London: DOH, 2007.

McEwen J. Consensus statement. Education Department of Marie Curie Cancer Care, Scotland.

Day NE , Williams DRR , Khaw KT. Development of a monitoring and evaluation system. Br J Cancer 1989; 59: 954–958.

Quinn M , Allen E on behalf of the United Kingdom Association of Cancer Registries. Changes in incident of and mortality from breast cancer in England and Wales since introduction of screening. Br Med J 1995; 311: 1391–1395.

Editorial. Number of deaths from cancers falls after 20 years of screening. Br Med J 2008; 336: 527.

Page L. Performed by the Pyramid Theatre Company (Bryntiron, Pennygros Road, Caerbryn, Ammanford, Dyfed, SA18 3DQ).